Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers

Inclusion Criteria:

* PRE-REGISTRATION INCLUSION CRITERIA
* Ability to understand and willingness to sign a written informed consent document and follow study procedures
* Willingness to abstain from grapefruit juice, alcohol, and concomitant medications during study
* Willingness to employ adequate contraception for men and women of childbearing potential; acceptable methods include double barrier methods, intrauterine device (IUD), postmenopausal status documented by serum follicle-stimulating hormone (FSH), and/or documentation of surgical sterilization
* Body mass index \< 35 kg/m\^2
* Willingness to provide blood and tissue specimens for research purposes
* REGISTRATION INCLUSION CRITERIA
* Participants must have normal organ function and have normal laboratory findings without clinically significant findings
* Satisfactory anesthesia and intestinal preparation, with no findings of advanced adenoma, chronic inflammation, or cancer

Exclusion Criteria:

* PRE-REGISTRATION EXCLUSION CRITERIA
* Previous personal history of advanced adenomas (\>= 1 cm in maximal diameter, \>= 3 in total number, villous morphology, or high-grade dysplasia) or colorectal cancer
* Family history of polyposis syndrome (e.g., familial adenomatous polyposis \[FAP\], hereditary non-polyposis colorectal cancer \[HNPCC\]) or colorectal cancer (first degree relatives younger than 60 years old)
* History of gastroparesis
* History of surgery involving the luminal gastrointestinal (GI) tract, including bariatric surgery
* History of celiac disease
* Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
* Irritable bowel syndrome, chronic constipation, functional bowel disorders, or colonic motility disorder
* Any malignancy within 3 years of baseline; participants with a history of basal cell or squamous cell skin cancer may be enrolled at the discretion of the investigator
* Participants may not be receiving any other investigational agents
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to linaclotide
* History of difficulty with colonoscopy or abnormal colorectal anatomy
* Uncontrolled current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Pregnant or lactating women
* Use of laxatives more than 3 times per week
* Intestinal motility agents, histamine-2 inverse agonists (H-2 blockers), or proton pump inhibitors
* Current use of \>= 5 cigarettes/day
* Current use of \>= 3 alcoholic drinks/day
* Use anti-platelet agents within two weeks of anticipated colonoscopy
* Use of anti-coagulants within two weeks of anticipated colonoscopy
* History of bleeding/coagulation problems
* Prior intolerance of or contraindications for the use of sedation or anesthetic agents, which would prevent the safe use of sedation for colonoscopy; this includes allergies to eggs and soy products
* Any medical condition judged by the investigator to constitute a risk to safe participation
* REGISTRATION EXCLUSION CRITERIA
* Colonoscopic finding requiring clinical intervention
* Use of any illicit or illegal substances detected by urinary drug screen
* Inadequate pre-intervention bowel preparation, as determined by the study physician